4//SEC Filing
Bellinger Andrew 4
Accession 0001209191-22-051374
CIK 0001840574other
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 5:00 PM ET
Size
18.3 KB
Accession
0001209191-22-051374
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-09-23$34.67/sh−6,632$229,905→ 19,997 total - Exercise/Conversion
Common Stock
2022-09-23$1.48/sh+20,000$29,600→ 26,629 total - Sale
Common Stock
2022-09-23$35.59/sh−13,368$475,803→ 6,629 total - Sale
Common Stock
2022-09-23$35.31/sh−36,798$1,299,304→ 9,831 total - Exercise/Conversion
Stock Option (right to buy)
2022-09-23−20,000→ 23,198 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2022-09-23$1.48/sh+40,000$59,200→ 46,629 total - Sale
Common Stock
2022-09-23$36.03/sh−3,202$115,380→ 6,629 total - Exercise/Conversion
Stock Option (right to buy)
2022-09-23−40,000→ 96,995 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (40,000 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), and (5) of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.26 to $36.15, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.88, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.92 to $36.15, inclusive.
- [F6]The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864116
Filing Metadata
- Form type
- 4
- Filed
- Sep 26, 8:00 PM ET
- Accepted
- Sep 27, 5:00 PM ET
- Size
- 18.3 KB